Zanubrutinib is showing favorable real-world performance in a nationwide Chinese analysis covering 410 patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), adding to evidence outside of pivotal clinical trials. The study, published in BMC Cancer, tracks patients treated across regional centers and focuses on how outcomes and tolerability align with existing clinical expectations in routine care settings. The report is positioned as detailed post-launch evidence that can inform clinician decision-making around next-line and combination treatment planning. Industry attention now typically turns to how real-world data compare on effectiveness endpoints and adverse-event profiles versus trial populations—especially for long-term disease control strategies in CLL/SLL.